Sarepta Therapeutics, Q4 and SRPT

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
Operator Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call. As a reminder, today's program is being recorded. At this time, I'd like to turn the call over to Mary Jenkins,
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was 7.8% below analysts’ consensus estimates.
Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -19.79% and 2.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics: Q4 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported fourth-quarter profit of $159 million. On a per-share basis, the Cambridge, Massachusetts-based company said it had net income of $1.50.
Sarepta Therapeutics (SRPT) Gets a Buy from Evercore ISI
In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report),
Sarepta Therapeutics Q4 earnings beat estimates, stock falls on higher expenses
CAMBRIDGE, Mass. - Sarepta Therapeutics (NASDAQ: SRPT) reported fourth quarter earnings that beat analyst expectations, but the stock fell 4.6% as investors focused on rising expenses.
Sarepta reports Q4 adjusted EPS $1.90, consensus $2.06
Reports Q4 revenue $658.4M, consensus $631.03M. “2024 performance represented the fruition of our multi-year strategy to become a ...
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
FierceBiotech2d
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...
BioPharma Dive8d
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...